RLAYRelay Therapeutics, Inc.

$2B

FY 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$15M+53.4% YoY

Gross Profit

$12M76.8% margin

Operating Income

-$303M-1971.6% margin

Net Income

-$276M-1800.6% margin

EPS (Diluted)

$-1.61

Cash Flow

Operating Cash Flow

-$235M

Free Cash Flow

-$236M

Stock-Based Comp.

$62M

Balance Sheet

Total Assets

$621M

Total Liabilities

$54M

Stockholders' Equity

$567M

Cash & Equivalents

$84M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$15M	$10M	+53.4%
Gross Profit	$12M	$10M	+17.9%
Operating Income	-$303M	-$372M	+18.7%
Net Income	-$276M	-$338M	+18.1%

RLAY FY 2025 Earnings — Relay Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena